Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Dr Christian SUEUR, GRECC, novembre 2019. 2e version WORK in PROGRESS Il est à noter que, jusqu'aux années 2010, c'étaient les études et méta-analyses épidémiologiques qui "insistaient" sur la "dangerosité" du cannabis, en particulier sur les "pré" et jeunes adolescents, quant au risque de neurotoxicité, et vis à vis de la "production" de psychoses chroniques, liées à la consommation de cannabis cf mon article : Les méta-analyses et le cannabis, ou la négation du savoir clinique 21 Septembre 2011 Dr. Christian Sueur, Psychiatre, praticien hospitalier http://tdme.free.fr/?p=2730#annot8 https://www.grecc.org/publications/dossiers-scientifiques/les-meta-analyses-et-le-cannabis-ou-la-negation-du-savoir-clinique-21-sep-2011-dr-christian-sueur/ Aujourd'hui, on peut constater la raréfaction de ce type d'études épidémiologiques, qui étaient, [...]
Lire la suitePsychiatry & the psychedelic drugs. Past, present & future James J.H. Rucker, Jonathan Iliff, David J. Nutt Neuropharmacology, 2018, 142, 200e218 https://doi.org/10.1016/j.neuropharm.2017.12.040 a b s t r a c t The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to [...]
Lire la suiteResearch ethics aspects of experimentation with LSD on human subjects : a historical and ethical review Bodnár Kristóf János, Kakuk Péter Medicine, Health Care and Philosophy © Springer Nature B.V. 2018 https://doi.org/10.1007/s11019-018-9871-9 Abstract In this paper our aim is to examine whether research conducted on human participants with LSD-25 (lysergic acid diethylamide) raises unique research ethical questions or demands particular concerns with regard to the design, conduct and follow-up of these studies, and should this be the case, explore and describe those issues. Our analysis is based on reviewing publications up to date which examine the clinical, research and other uses of LSD and those addressing [...]
Lire la suiteSome distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity Rachael Ingram, Heather Kang, Stafford Lightman, David E. Jane, Zuner A. Bortolotto, Graham L. Collingridge, David Lodge, Arturas Volianskis Neuropharmacology, 2018, 142, 30e40 https://doi.org/10.1016/j.neuropharm.2018.06.008 Abstract Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, which may arise from a combination of several inter-related actions. Firstly, reductions of the contribution of NMDA receptors to afferent information from external and internal sensory inputs may distort sensations and their processing in higher brain centres. Secondly, reductions of NMDA receptormediated excitation of GABAergic interneurons can result in [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteCannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suitePreclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129 Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]
Lire la suiteEndocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna, Medical University of Lodz, Lodz, Poland Encyclopedia of Gastroenterology, 2nd Edition © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs [...]
Lire la suiteThe endocannabinoid system : an overview Natalia Battista, Monia Di Tommaso, Monica Bari and Mauro Maccarrone Frontiers in Behavioral Neuroscience, 2012|Volume 6|Article 9 | 1 doi: 10.3389/fnbeh.2012.00009 Upon the identification of anandamide (AEA) in the porcine brain, numerous studies contributed to the current state of knowledge regarding all elements that form the “endocannabinoidsystem (ECS).” How this complex system of receptors, ligands, and enzymes is integrated in helping to regulate fundamental processes at level of central nervous and peripheral systems and how its regulation and dysregulation might counteract disturbances of such functions, is now a days still under investigation. However, the most recent advances on [...]
Lire la suiteCannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8. 1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]
Lire la suite